Avalo scores Phase 2 success in comeback bid, raises $375M

May 6, 2026 11:00 AM EDT FinancingR&D Ava­lo scores much-need­ed Phase 2 win and $375M raise as it at­tempts turn­around Max Gelman Senior Editor Ava­lo Ther­a­peu­tics’ come­back bid surged for­ward Tues­day af­ter­noon, as the im­munol­o­gy biotech se­cured a mid-stage tri­al win in an in­flam­ma­to­ry skin dis­or­der. Ava­lo Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER